Genetic polymorphisms in UGT genes can result in altered enzyme activity, ranging from complete loss of function to increased activity. These variations can affect the pharmacokinetics of drugs, leading to variability in drug response among individuals. For instance, polymorphisms in the UGT1A1 gene are known to influence the metabolism of the anti-cancer drug irinotecan, affecting both its efficacy and the risk of adverse effects.
